Original Article
Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome
N Engl J Med 2006; 354:261-269January 19, 2006
- Abstract
Background
Women with the Lynch syndrome (hereditary nonpolyposis colorectal cancer) have a 40 to 60 percent lifetime risk of endometrial cancer and a 10 to 12 percent lifetime risk of ovarian cancer. The benefit of prophylactic gynecologic surgery for women with this syndrome has been uncertain. We designed this study to determine the reduction in the risk of gynecologic cancers associated with prophylactic hysterectomy and bilateral salpingo-oophorectomy in women with the Lynch syndrome.
Methods
Three hundred fifteen women with documented germ-line mutations associated with the Lynch syndrome were identified. Women who had undergone prophylactic hysterectomy (61 women) and women who had undergone prophylactic bilateral salpingo-oophorectomy (47 women) were matched with mutation-positive women who had not undergone the procedure in question (210 women for the analysis of endometrial cancer and 223 for the analysis of ovarian cancer). Women who had undergone prophylactic surgery and their matched controls were followed from the date of the surgery until the occurrence of cancer or until the data were censored at the time of the last follow-up visit.
Results
There were no occurrences of endometrial, ovarian, or primary peritoneal cancer among the women who had undergone prophylactic surgery. Endometrial cancer was diagnosed in 69 women in the control group (33 percent), for an incidence density of 0.045 per woman-year, yielding a prevented fraction (the proportion of potential new cancers prevented) of 100 percent (95 percent confidence interval, 90 to 100 percent). Ovarian cancer was diagnosed in 12 women in the control group (5 percent), for an incidence density of 0.005 per woman-year, yielding a prevented fraction of 100 percent (95 percent confidence interval, −62 to 100 percent).
Conclusions
These findings suggest that prophylactic hysterectomy with bilateral salpingo-oophorectomy is an effective strategy for preventing endometrial and ovarian cancer in women with the Lynch syndrome.
Media in This Article
Figure 1
Cumulative Incidence of Endometrial Cancer among Women with the Lynch Syndrome Who Underwent Prophylactic Hysterectomy and Those Who Did Not.Figure 2
Cumulative Incidence of Ovarian Cancer among Women with the Lynch Syndrome Who Underwent Prophylactic Bilateral Salpingo-Oophorectomy (BSO) and Those Who Did Not.Article Activity
- Article
The Lynch syndrome (hereditary nonpolyposis colorectal cancer) is an autosomal dominant cancer-susceptibility syndrome caused by a germ-line mutation in one of the DNA-mismatch repair genes.1-4 It is associated with an early onset of cancer and the development of multiple types of cancer, including cancer of the colon and rectum, endometrium, ovary, small bowel, ureter, and renal pelvis. The lifetime risk of endometrial cancer for women with the Lynch syndrome is 40 to 60 percent, which equals or exceeds their risk of colorectal cancer. In addition, they have a 10 to 12 percent lifetime risk of ovarian cancer.5,6
Up to the present, data have been lacking on the basis of which to evaluate the efficacy of gynecologic surgery performed to reduce the risk of cancer in women with the Lynch syndrome. In 1997, the Cancer Genetics Studies Consortium reviewed the available evidence regarding the efficacy of prophylactic hysterectomy and bilateral salpingo-oophorectomy and published a consensus statement concluding that there was insufficient evidence for it to recommend whether or not women with the Lynch syndrome should have prophylactic surgery to reduce the risk of gynecologic cancer.7 Despite the lack of evidence, several authors have suggested that hysterectomy with bilateral salpingo-oophorectomy is a reasonable preventive strategy for women with the Lynch syndrome, after they have completed childbearing.8-10 We conducted a study to determine whether the risk of gynecologic cancers among women with the Lynch syndrome was reduced after hysterectomy and bilateral salpingo-oophorectomy.
Methods
Study Patients
Approval for this study, with a waiver of informed consent, was obtained from the institutional review board at each of the participating institutions. The records of patients enrolled in hereditary-cancer registries from 1973 to 2004 were reviewed. We identified 380 women with documented MLH1, MSH2, or MSH6 germ-line mutations from registries at Creighton University (284 women), the University of Texas M.D. Anderson Cancer Center (72 women), and the University of California at San Francisco (24 women). Women with genetic variants of unknown functional significance were excluded. The study was based on the 315 women (83 percent of the total) for whom follow-up information was available.
Registry databases and patients' medical records were reviewed to obtain information on demographic characteristics, genetic testing results, and vital status. Surgical information and occurrences of cancer were verified by reviews of medical records, operative notes, and pathology reports.
Endometrial Cancer
To determine whether prophylactic surgery reduced the risk of endometrial cancer, we performed a retrospective cohort analysis of women with germ-line mutations. In this analysis, we compared the outcome among those who had undergone hysterectomy either to prevent cancer or to treat benign conditions with the outcome among women who had not undergone hysterectomy (controls). We matched each woman who had undergone hysterectomy with one or more control women by a method similar to that used by Rebbeck et al.11 Control women were of similar age to the women with whom they were matched (i.e., their dates of birth were within five years of each other), had been treated at the same institutions, and had been alive, with an intact uterus and no history of gynecologic cancer, at the time the women with whom they were matched underwent hysterectomy. Sixty-one women who had undergone hysterectomy, with or without salpingo-oophorectomy, were matched with 210 controls. Forty-four potential controls could not be matched with case women because their dates of birth did not fall within five years of that of any woman who had undergone hysterectomy, and therefore they were not included in the analysis.
Ovarian Cancer
We performed a similar analysis to evaluate the reduction in the risk of ovarian cancer after prophylactic surgery. Women who had undergone bilateral salpingo-oophorectomy for preventive reasons or to treat benign conditions were matched with one or more mutation-positive control women who were of similar age (date of birth within five years), had been treated at the same institution, had not undergone prophylactic bilateral salpingo-oophorectomy, and had been alive, with both ovaries intact and no history of gynecologic cancer, at the time the women with whom they were matched underwent bilateral salpingo-oophorectomy. On the basis of these criteria, 47 women who had undergone prophylactic bilateral salpingo-oophorectomy were matched with 223 controls. Forty-five potential controls could not be matched with case women because their dates of birth did not fall within five years of that of any woman who had undergone bilateral salpingo-oophorectomy, and therefore they were not included in the analysis.
Statistical Analysis
The women who had undergone prophylactic surgery and the controls were followed from the date of the prophylactic surgery until the occurrence of endometrial, ovarian, or primary peritoneal cancer or until the observations were censored as of the date of death or the date of the last contact. The primary end point was the development of endometrial, ovarian, or primary peritoneal cancer. The incidence density12 (the number of cancers divided by the number of years the women were at risk) was calculated for endometrial, ovarian, and primary peritoneal cancer in each group. The prevented fraction12 ([incidence density for controls−incidence density for women who underwent surgery]÷[incidence density for controls]), or the proportion of potential new cancers prevented, was estimated with the 95 percent confidence interval. The cumulative incidence of cancer was estimated by the method of Kaplan and Meier.13 All analyses were performed with Stata (version 8.0) and S-PLUS 2000 software.
Results
Of the 315 women with germ-line mutations, 61 (19 percent) underwent gynecologic surgery for preventive reasons or to treat benign conditions. Forty-seven of these women underwent both hysterectomy and bilateral salpingo-oophorectomy, and 14 women underwent hysterectomy only. None of the women in our study underwent bilateral salpingo-oophorectomy without hysterectomy. Thirty-eight percent had genetic testing before undergoing prophylactic surgery. The characteristics of the entire study population are shown in Table 1Table 1
Characteristics of the 315 Women in the Study Population.. There were no significant differences among the participating institutions in the proportion of women who underwent prophylactic surgery. There were also no significant differences in the proportions of women with MLH1, MSH2, or MSH6 mutations between the group of women who underwent prophylactic surgery and the group who did not. Eighty-five percent of the women who had undergone prophylactic surgery, and 82 percent of the women who had not, were parous.Endometrial Cancer
Of the women who underwent prophylactic hysterectomy, none subsequently had endometrial cancer, as compared with 69 women (33 percent) in the control group (Table 2Table 2
Reduction in the Risk of Endometrial Cancer after Prophylactic Hysterectomy.). The incidence density was 0.000 per woman-year for the women who underwent prophylactic hysterectomy and 0.045 per woman-year for the controls (P<0.001), yielding a prevented fraction of 100 percent (95 percent confidence interval, 90 to 100 percent). The cumulative incidence of endometrial cancer for each group is illustrated in Figure 1Figure 1Cumulative Incidence of Endometrial Cancer among Women with the Lynch Syndrome Who Underwent Prophylactic Hysterectomy and Those Who Did Not.. The median age at prophylactic hysterectomy was 41 years (range, 20 to 63), and the median age at the diagnosis of endometrial cancer was 46 years (range, 30 to 69). Four endometrial cancers (6 percent) were diagnosed in women under 35 years of age. The women who underwent prophylactic hysterectomy were followed for an average of 13.3 years (range, 0.5 to 38.0) after surgery, and the controls were followed for an average of 7.4 years (range, 0.1 to 35.0) after the time of the matched woman's surgery. The distribution of patients according to the stage of endometrial cancer at diagnosis is shown in Table 2.Among women who did not undergo prophylactic hysterectomy, endometrial cancer developed in 22 of those who had an MLH1 mutation (28 percent), 47 of those with an MSH2 mutation (37 percent), and none of those with an MSH6 mutation. The differences among these figures are not statistically significant. Ninety-two percent of the patients underwent genetic testing after receiving a diagnosis of endometrial cancer. Endometrial cancers were incidentally diagnosed in three women at the time of prophylactic hysterectomy. Two of the patients had stage I disease and one patient had stage II disease. They underwent surgery at 38, 58, and 48 years of age, respectively, and are currently alive, without any evidence of disease, 27, 2, and 4 years after surgery.
At the time of the analysis, 25 women (9 percent) had died. Twenty-two of these women (10 percent) were from the control group and three (5 percent) had undergone prophylactic surgery. The causes of death among the women in the control group were endometrial cancer (three women), ovarian and colon cancer (one woman), colon cancer (seven women), other Lynch syndrome–related cancers (four women), other cancers (two women), cardiac disease (one woman), and unknown (four women). The causes of death for the three women who underwent prophylactic surgery were colon cancer, brain cancer, and bladder cancer.
Ovarian Cancer
Of the 47 women who had undergone bilateral salpingo-oophorectomy at the time of their hysterectomy for cancer prevention or for benign conditions, none subsequently had ovarian cancer, as compared with 12 of the controls (5 percent) (Table 3Table 3
Reduction in the Risk of Ovarian Cancer after Prophylactic Bilateral Salpingo-Oophorectomy.). One of the women who had ovarian cancer had previously undergone hysterectomy for a benign condition without bilateral salpingo-oophorectomy. The incidence density was 0.000 per woman-year for the women who had undergone surgery and 0.005 per woman-year for the controls (P=0.09). The prevented fraction was 100 percent (95 percent confidence interval, −62 to 100 percent). The cumulative incidence of ovarian cancer for each group is illustrated in Figure 2Figure 2Cumulative Incidence of Ovarian Cancer among Women with the Lynch Syndrome Who Underwent Prophylactic Bilateral Salpingo-Oophorectomy (BSO) and Those Who Did Not..The median age at prophylactic bilateral salpingo-oophorectomy was 41 years (range, 20 to 58), and the median age at the diagnosis of ovarian cancer was 42 years (range, 31 to 48). Two (17 percent) of the ovarian cancers were diagnosed in women before the age of 35. The average follow-up was 11.2 years (range, 0.5 to 38.0) after surgery among women who had undergone prophylactic bilateral salpingo-oophorectomy and 10.6 years (range, 0.1 to 41.0) after the time of the matched woman's surgery among the control women. The distribution of women according to the stage of ovarian cancer at diagnosis is shown in Table 3.
Among the women who did not undergo prophylactic bilateral salpingo-oophorectomy, ovarian cancer developed in five of those with an MLH1 mutation (6 percent), seven of those with an MSH2 mutation (5 percent), and none of those with an MSH6 mutation (P not significant). None of the women who underwent prophylactic hysterectomy with bilateral salpingo-oophorectomy subsequently had primary peritoneal cancer. Of the 12 cases of ovarian cancer, 3 (25 percent) were synchronous primary cancers of the ovary and endometrium according to the criteria of Scully et al.14 No cases of ovarian cancer were incidentally diagnosed at the time of prophylactic bilateral salpingo-oophorectomy.
Surgical Complications
Surgical complications were noted in 1 of the 61 women who underwent prophylactic surgery (1.6 percent). The patient was a 27-year-old woman who had received a diagnosis of rectal carcinoma two years previously and had been treated by rectosigmoid resection with colostomy and creation of a Hartmann's pouch, followed by radiation therapy. At the time of prophylactic abdominal hysterectomy with bilateral salpingo-oophorectomy, a ureteral injury occurred and was repaired. The patient subsequently had a ureterovaginal fistula as well as a ureteroenteral fistula to the Hartmann's pouch and underwent a ureteroneocystostomy. She later had a rectovaginal fistula, which she decided not to have repaired.
Metachronous Colorectal and Endometrial or Ovarian Cancer
In our cohort, 107 women (34 percent) received a diagnosis of colorectal cancer. Forty-one patients had synchronous (3 patients) or metachronous (38 patients) colorectal cancer and endometrial or ovarian cancer (32 and 9 patients, respectively). The median age at the diagnosis of colorectal cancer was 47 years (range, 26 to 77). Five of the 41 women (12 percent) were 35 years old or younger, 6 (15 percent) were 36 to 40 years of age, 5 (12 percent) were 41 to 45 years of age, and 25 (61 percent) were over the age of 45. Twenty-one of these 41 women (51 percent) received a diagnosis of gynecologic cancer after receiving a diagnosis of and undergoing surgery for colorectal cancer. The median time between the diagnoses of colon cancer and gynecologic cancer was 5 years (range, 1 to 25).
Discussion
This study provides evidence of a benefit of prophylactic hysterectomy and bilateral salpingo-oophorectomy in preventing gynecologic cancers in women with the Lynch syndrome. In our cohort, there were no new cases of endometrial or ovarian cancer among the women who underwent prophylactic surgery. The reduction in the number of cancer cases was statistically significant for endometrial cancer but not for ovarian cancer; however, the power of the latter comparison was limited by the small number of ovarian cancers diagnosed in our cohort.
The median age at diagnosis was 46 years for endometrial cancer and 42 years for ovarian cancer. These numbers are consistent with those in previous studies of women with the Lynch syndrome that have found a mean age at diagnosis of 48 to 49 years for endometrial cancer15,16 and 42 years for ovarian cancer,17 with the majority of cancers diagnosed in women after the age of 35. These findings support consideration of prophylactic hysterectomy and bilateral salpingo-oophorectomy in women with the Lynch syndrome after the age of 35, or once childbearing has been completed.
There is currently limited information on the efficacy of surveillance in reducing the risk of endometrial and ovarian cancer in women with the Lynch syndrome.18,19 Current screening guidelines for gynecologic cancer recommend annual pelvic examinations, transvaginal ultrasonography, endometrial biopsy, and measurements of serum CA-125 levels beginning at 25 to 35 years of age,7 but controlled studies are lacking to support these methods in young premenopausal women. Information regarding screening for endometrial and ovarian cancer was not available for our cohort. Further research is needed to determine the efficacy of these screening methods in comparison with prophylactic surgery in reducing morbidity and mortality from endometrial and ovarian cancer in women with the Lynch syndrome.
The disadvantages of prophylactic hysterectomy and bilateral salpingo-oophorectomy include surgical complications and premature menopause. The most common complications associated with hysterectomy and bilateral salpingo-oophorectomy are bleeding, infection, and injuries to the urinary tract and bowel. In our study, the surgical complication rate was 1.6 percent. This figure is consistent with previously published complication rates of 1 to 9 percent associated with hysterectomy and bilateral salpingo-oophorectomy for benign conditions.20-22 In premenopausal women, bilateral salpingo-oophorectomy results in premature menopause, with attendant symptoms (including hot flashes, vaginal dryness, sexual dysfunction, and sleep disturbances) and an increased risk of osteoporosis.23-25 Many of these conditions can usually be managed with hormonal or nonhormonal medications.26 Information regarding these side effects was not available for our cohort.
None of the women in our cohort received a diagnosis of primary peritoneal cancer after prophylactic bilateral salpingo-oophorectomy; however, our sample size and follow-up time were limited. Previous studies involving women with BRCA mutations have reported an incidence of primary peritoneal cancer after prophylactic bilateral salpingo-oophorectomy of 0.8 to 1.0 percent.11,27 The risk of primary peritoneal cancer among women with the Lynch syndrome after prophylactic bilateral salpingo-oophorectomy remains uncertain.
Three women who underwent prophylactic hysterectomy were found to have occult endometrial carcinomas at the time of surgery. This finding emphasizes the need to maintain a high index of suspicion during prophylactic surgery in women with the Lynch syndrome.28 Preoperative assessment with endometrial biopsy, transvaginal ultrasonography, and measurement of CA-125 levels should be considered. The uterus and ovaries should be carefully assessed at the time of surgery; the pathologist should be advised of the high risk of endometrial and ovarian cancer, and the specimens should be carefully examined intraoperatively, with frozen sections obtained if indicated. The surgeon should be prepared to perform a complete staging operation, if necessary.
In our cohort, 41 of 315 women (13 percent) received a diagnosis of synchronous or metachronous colorectal cancer and endometrial or ovarian cancer. Thirty-six of these women (88 percent) were older than 35 years at the time of their diagnosis of colorectal cancer. In 21 of these women, the gynecologic cancer was diagnosed after the woman had undergone treatment for colorectal cancer and could have been prevented if prophylactic hysterectomy and bilateral salpingo-oophorectomy had been performed at the time of surgery for colorectal cancer.
Vasen et al.15 evaluated the lifetime cancer risks associated with different gene mutations in 138 families in which the Lynch syndrome occurred. They found the risks of both endometrial cancer and ovarian cancer to be higher in MSH2 mutation carriers than in MLH1 mutation carriers, but the differences were not statistically significant. Similarly, we did not detect significant differences in the incidence of endometrial or ovarian cancer among women with MLH1, MSH2, and MSH6 mutations, but the power of this analysis was limited by our small sample size.
A limitation of our study is that the data were collected retrospectively. Many of the women in our cohort underwent prophylactic surgery or received a diagnosis of cancer before they had undergone genetic testing. We did not have information on body-mass index or other risk factors for gynecologic cancers. In addition, we were unable to assess the effects of prophylactic surgery on survival and on deaths related to gynecologic cancer. Further studies with longer follow-up will be needed to assess the differences in survival between women who undergo prophylactic gynecologic surgery and those who do not.
In summary, this study provides evidence of the efficacy of prophylactic surgery in preventing gynecologic cancers in women with the Lynch syndrome. Preoperative counseling should address the trade-offs between the reduction in the risk of cancer and the risks and side effects of surgery, as well as the uncertainties regarding surveillance of gynecologic cancer as an alternative management approach.
Supported in part by a grant from the National Cancer Institute (N01-CN-05127).
No potential conflict of interest relevant to this article was reported.
We are indebted to Dr. Patrick M. Lynch, Dr. Russell R. Broaddus, and the Lynch syndrome registry at the University of Texas M.D. Anderson Cancer Center; to Mrs. Jane F. Lynch, Mr. William C. Dowart, and the Creighton University Lynch syndrome registry; and to Dr. Jonathan P. Terdiman, Ms. Amie M. Blanco, and the University of California at San Francisco Colorectal Cancer Prevention Program Familial Gastrointestinal Cancer Registry.
Source Information
From the Departments of Gynecologic Oncology (K.M.S., P.T.S., K.G.W., S.G.B.-R., C.C.S., B.M.S., D.M.G., K.H.L.), Biostatistics and Applied Mathematics (M.F.M.), and Clinical Cancer Genetics (M.S.D.), the University of Texas M.D. Anderson Cancer Center, Houston; the Department of Preventive Medicine, Creighton University, Omaha, Nebr. (H.T.L., M.B.C.); and the Departments of Gynecologic Oncology (L.C., K.Y.Y., M.M.R.) and Medicine (P.G.C.), University of California at San Francisco, San Francisco.
Address reprint requests to Dr. Lu at the Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, P.O. Box 301439, Unit 1362, Houston, TX 77230-1439, or at khlu@mdanderson.org.
- References
References
1
Leach FS ,Nicolaides NC ,Papadopoulos N , et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-1225
CrossRef | Web of Science | Medline2
Fishel R ,Lescoe MK ,Rao MR , et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-1038[Erratum, Cell 1994;77:167.]
CrossRef | Web of Science | Medline3
Papadopoulos N ,Nicolaides NC ,Wei YF , et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263:1625-1629
CrossRef | Web of Science | Medline4
Kolodner RD ,Tytell JD ,Schmeits JL , et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999;59:5068-5074
Web of Science | Medline5
Aarnio M ,Sankila R ,Pukkala E , et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-218
CrossRef | Web of Science | Medline6
Dunlop MG ,Farrington SM ,Carothers AD , et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-110
CrossRef | Web of Science | Medline7
Burke W ,Petersen G ,Lynch P , et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. JAMA 1997;277:915-919
CrossRef | Web of Science | Medline8
Bertagnolli MM . Surgical prevention of cancer. J Clin Oncol 2005;23:324-332
CrossRef | Web of Science | Medline9
Lynch HT ,Watson P ,Shaw TG , et al. Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: Hereditary nonpolyposis colorectal carcinoma as a model. Cancer 1999;86:Suppl 11:2457-2463
CrossRef | Web of Science | Medline10
Lu KH ,Dinh M ,Kohlmann W , et al. Gynecologic cancer as a “sentinel cancer“ for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005;105:569-574
CrossRef | Web of Science | Medline11
Rebbeck TR ,Lynch HT ,Neuhausen SL , et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622
Full Text | Web of Science | Medline12
Kleinbaum DG, Kupper LL, Morganstern H. Epidemiologic research. New York: Van Nostrand Reinhold, 1982.
13
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science14
Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. In: Scully RE, Young RH, Clement PB. Atlas of tumor pathology. Bethesda, Md.: Armed Forces Institute of Pathology, 1998:125-6.
15
Vasen HF ,Stormorken A ,Menko FH , et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001;19:4074-4080
Web of Science | Medline16
Boks DE ,Trujillo AP ,Voogd AC ,Morreau H ,Kenter GG ,Vasen HF . Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002;102:198-200
CrossRef | Web of Science | Medline17
Watson P ,Butzow R ,Lynch HT , et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001;82:223-228
CrossRef | Web of Science | Medline18
Dove-Edwin I ,Boks D ,Goff S , et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94:1708-1712
CrossRef | Web of Science | Medline19
Rijcken FE ,Mourits MJ ,Kleibeuker JH ,Hollema H ,van der Zee AG . Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003;91:74-80
CrossRef | Web of Science | Medline20
Kovac SR . Hysterectomy outcomes in patients with similar indications. Obstet Gynecol 2000;95:787-793
CrossRef | Web of Science | Medline21
Weber AM ,Lee JC . Use of alternative techniques of hysterectomy in Ohio, 1988-1994. N Engl J Med 1996;335:483-489[Erratum, N Engl J Med 1996;335:1406.]
Full Text | Web of Science | Medline22
Goodno JA Jr ,Powers TW ,Harris VD . Ureteral injury in gynecologic surgery: a ten-year review in a community hospital. Am J Obstet Gynecol 1995;172:1817-1820
CrossRef | Web of Science | Medline23
Prior JC ,Vigna YM ,Wark JD , et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 1997;12:1851-1863
CrossRef | Web of Science | Medline24
Graziottin A ,Basson R . Sexual dysfunction in women with premature menopause. Menopause 2004;11:766-777
CrossRef | Web of Science | Medline25
Menopause and the perimenopausal transition. In: Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. Baltimore: Lippincott Williams & Wilkins, 1999:662-7.
26
Anderson GL ,Limacher M ,Assaf AR , et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
CrossRef | Web of Science | Medline27
Kauff ND ,Satagopan JM ,Robson ME , et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615
Full Text | Web of Science | Medline28
Chung L ,Broaddus R ,Crozier M ,Luthraa R ,Levenback C ,Lu K . Unexpected endometrial cancer at prophylactic hysterectomy in a woman with hereditary nonpolyposis colon cancer. Obstet Gynecol 2003;102:1152-1155
CrossRef | Web of Science | Medline
- Citing Articles (133)
Citing Articles
1
Laura L. Holman, Karen H. Lu. (2012) Genetic Risk and Gynecologic Cancers. Hematology/Oncology Clinics of North America 26:1, 13-29
CrossRef2
Anne Lanceley, Zara Eagle, Gemma Ogden, Sue Gessler, Khalil Razvi, Jonathan A. Ledermann, Lucy Side. (2012) Family History and Women With Ovarian Cancer. International Journal of Gynecological Cancer 22:2, 254-259
CrossRef3
Celine H.M. Leenen, Margot G.F. van Lier, Helena C. van Doorn, Monique E. van Leerdam, Sjarlot G. Kooi, Judith de Waard, Robert F. Hoedemaeker, Ans M.W. van den Ouweland, Sanne M. Hulspas, Hendrikus J. Dubbink, Ernst J. Kuipers, Anja Wagner, Winand N.M. Dinjens, Ewout W. Steyerberg. (2012) Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. Gynecologic Oncology
CrossRef4
Cecelia A. Bellcross, Sara R. Bedrosian, Elvan Daniels, Debra Duquette, Heather Hampel, Kory Jasperson, Djenaba A. Joseph, Celia Kaye, Ira Lubin, Laurence J. Meyer, Michele Reyes, Maren T. Scheuner, Sheri D. Schully, Leigha Senter, Sherri L. Stewart, Jeanette St. Pierre, Judith Westman, Paul Wise, Vincent W. Yang, Muin J. Khoury. (2012) Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genetics in Medicine 14:1, 152-162
CrossRef5
Floor J. Backes, Elizabeth Mitchell, Heather Hampel, David E. Cohn. (2011) Endometrial cancer patients and compliance with genetic counseling: Room for improvement. Gynecologic Oncology 123:3, 532-536
CrossRef6
S. K. Warrier, A. H. Trainer, A. C. Lynch, C. Mitchell, R. Hiscock, S. Sawyer, A. Boussioutas, A. G. Heriot. (2011) Preoperative Diagnosis of Lynch Syndrome With DNA Mismatch Repair Immunohistochemistry on a Diagnostic Biopsy. Diseases of the Colon & Rectum 54:12, 1480-1487
CrossRef7
Akiva P. Novetsky, Leslie R. Boyd, John P. Curtin. (2011) Trends in Bilateral Oophorectomy at the Time of Hysterectomy for Benign Disease. Obstetrics & Gynecology 118:6, 1280-1286
CrossRef8
Christina M. Laukaitis. (2011) Genetics for the General Internist. The American Journal of Medicine
CrossRef9
Henry T Lynch, Douglas L Riegert-Johnson, Carrie Snyder, Jane F Lynch, Jill Hagenkord, C Richard Boland, Jennifer Rhees, Stephen N Thibodeau, Lisa A Boardman, Janine Davies, Roland P Kuiper, Nicoline Hoogerbrugge, Marjolijn J L Ligtenberg. (2011) Lynch Syndrome-Associated Extracolonic Tumors Are Rare in Two Extended Families With the Same EPCAM Deletion. The American Journal of Gastroenterology 106:10, 1829-1836
CrossRef10
Elena B. Elkin, Deborah A. Marshall, Nathalie A. Kulin, Ilia L. Ferrusi, Michael J. Hassett, Uri Ladabaum, Kathryn A. Phillips. (2011) Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genetics in Medicine 13:10, 853-860
CrossRef11
Matthew F. Kalady. (2011) Surgical Management of Hereditary Nonpolyposis Colorectal Cancer. Advances in Surgery 45:1, 265-274
CrossRef12
Kathleen Y. Yang, Aaron B. Caughey, Sarah E. Little, Michael K. Cheung, Lee-May Chen. (2011) A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families. Familial Cancer 10:3, 535-543
CrossRef13
Begoña Graña, Enrique Lastra, Gemma Llort, Joan Brunet, Dolores Isla. (2011) SEOM clinical guidelines for hereditary cancer. Clinical and Translational Oncology 13:8, 580-586
CrossRef14
Okechukwu Ibeanu, Susan C. Modesitt, Jennifer Ducie, Vivian von Gruenigen, Modupe Agueh, Amanda Nickles Fader. (2011) Hormone replacement therapy in gynecologic cancer survivors: Why not?. Gynecologic Oncology 122:2, 447-454
CrossRef15
Manish Gala, Daniel C. Chung. (2011) Hereditary Colon Cancer Syndromes. Seminars in Oncology 38:4, 490-499
CrossRef16
Lillias Holmes, Liliana Bordeianou. (2011) Screening and Prevention of Extracolonic Cancers in Patients with Hereditary Nonpolyposis Colon Cancer. Seminars in Colon and Rectal Surgery 22:2, 123-126
CrossRef17
Constantine P. Spanos. (2011) Sexual Function and Fertility Aspects in the Management of Hereditary Colorectal Cancer. Seminars in Colon and Rectal Surgery 22:2, 141-145
CrossRef18
V. Celentano, G. Luglio, G. Antonelli, R. Tarquini, L. Bucci. (2011) Prophylactic surgery in Lynch syndrome. Techniques in Coloproctology 15:2, 129-134
CrossRef19
Patrick M. Lynch. (2011) How Helpful Is Age at Colorectal Cancer Onset in Finding Hereditary Nonpolyposis Colorectal Cancer?. Clinical Gastroenterology and Hepatology 9:6, 458-460
CrossRef20
Jason Smith, Karen Crowe, Julie McGaughran, Thomas Robertson. (2011) Sebaceous adenoma arising within an ovarian mature cystic teratoma in Muir-Torre syndrome. Annals of Diagnostic Pathology
CrossRef21
Patrick M. Lynch. (2011) How Helpful Is Age at Colorectal Cancer Onset in Finding HNPCC?. Diseases of the Colon & Rectum 54:5, 515-517
CrossRef22
ANNIKA AURANEN, TITTA JOUTSINIEMI. (2011) A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstetricia et Gynecologica Scandinavica 90:5, 437-444
CrossRef23
Scott M. Weissman, Cecelia Bellcross, Christina Chimera Bittner, Mary E. Freivogel, Joy Larsen Haidle, Pardeep Kaurah, Anna Leininger, Selvi Palaniappan, Kelle Steenblock, Thuy M. Vu, Molly S. Daniels. (2011) Genetic Counseling Considerations in the Evaluation of Families for Lynch Syndrome—A Review. Journal of Genetic Counseling 20:1, 5-19
CrossRef24
Henry T. Lynch, Jane F. Lynch, Zoran Gatalica, Richard Boland. (2011) Lynch Syndrome: Its Phenotypic and Genotypic Heterogeneity. Viszeralmedizin 27:4, 266-273
CrossRef25
Manuel Ferrer Márquez, Ángel Reina Duarte, Vanesa Maturana Ibáñez, Ricardo Belda Lozano, Francisco Rubio Gil, Isabel Blesa Sierra, María del Mar Rico Morales. (2011) Lynch syndrome: Genetics and surgery. Cirugía Española (English Edition) 89:1, 3-9
CrossRef26
Jürgen Riemann, Gabriela Möslein. (2011) Hereditäre Tumorerkrankungen des Gastrointestinaltrakts. Viszeralmedizin 27:4, 329-335
CrossRef27
Fay Kastrinos, Ewout W. Steyerberg, Rowena Mercado, Judith Balmaña, Spring Holter, Steven Gallinger, Kimberly D. Siegmund, James M. Church, Mark A. Jenkins, Noralane M. Lindor, Stephen N. Thibodeau, Lynn Anne Burbidge, Richard J. Wenstrup, Sapna Syngal. (2011) The PREMM1,2,6 Model Predicts Risk of MLH1, MSH2, and MSH6 Germline Mutations Based on Cancer History. Gastroenterology 140:1, 73-81.e5
CrossRef28
Manuel Ferrer Márquez, Ángel Reina Duarte, Vanesa Maturana Ibáñez, Ricardo Belda Lozano, Francisco Rubio Gil, Isabel Blesa Sierra, María del Mar Rico Morales. (2011) Síndrome de Lynch: genética y cirugía. Cirugía Española 89:1, 3-9
CrossRef29
Kenta Masuda, Kouji Banno, Megumi Yanokura, Yusuke Kobayashi, Iori Kisu, Arisa Ueki, Asuka Ono, Nana Asahara, Hiroyuki Nomura, Akira Hirasawa, Nobuyuki Susumu, Daisuke Aoki. (2011) Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer. Molecular Biology International 2011, 1-6
CrossRef30
Fay Kastrinos, Sapna Syngal. (2011) Inherited Colorectal Cancer Syndromes. The Cancer Journal 17:6, 405-415
CrossRef31
Andreas Obermair, Danny R. Youlden, Joanne P. Young, Noralane M. Lindor, John A. Baron, Polly Newcomb, Susan Parry, John L. Hopper, Robert Haile, Mark A. Jenkins. (2010) Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. International Journal of Cancer 127:11, 2678-2684
CrossRef32
Neel B. Shah, Noralane M. Lindor. (2010) Lower Gastrointestinal Tract Cancer Predisposition Syndromes. Hematology/Oncology Clinics of North America 24:6, 1229-1252
CrossRef33
Elena M. Stoffel, Anu Chittenden. (2010) Genetic Testing for Hereditary Colorectal Cancer: Challenges in Identifying, Counseling, and Managing High-Risk Patients. Gastroenterology 139:5, 1436-1441.e1
CrossRef34
John O. Schorge, Susan C. Modesitt, Robert L. Coleman, David E. Cohn, Noah D. Kauff, Linda R. Duska, Thomas J. Herzog. (2010) SGO White Paper on Ovarian Cancer: Etiology, Screening and Surveillance. Gynecologic Oncology 119:1, 7-17
CrossRef35
Christine Nyiraneza, Etienne Marbaix, Mireille Smets, Christine Galant, Christine Sempoux, Karin Dahan. (2010) High risk for neoplastic transformation of endometriosis in a carrier of lynch syndrome. Familial Cancer 9:3, 383-387
CrossRef36
Kaylene J. Ready, Molly S. Daniels, Charlotte C. Sun, Susan K. Peterson, Hope Northrup, Karen H. Lu. (2010) Obstetrics/Gynecology Residents’ Knowledge of Hereditary Breast and Ovarian Cancer and Lynch Syndrome. Journal of Cancer Education 25:3, 401-404
CrossRef37
Deborah Rabinowitz-Abrams, Debra Morgan, James Morse, Susan Miesfeldt. (2010) Building a Tool to Identify Risk for Lynch Syndrome Among Individuals Presenting for Screening Colonoscopy. Journal of Genetic Counseling 19:4, 353-359
CrossRef38
Simon A Gayther, Paul DP Pharoah. (2010) The inherited genetics of ovarian and endometrial cancer. Current Opinion in Genetics & Development 20:3, 231-238
CrossRef39
Pedro Pérez Segura, Carmen Guillén Alonso, Teresa Ramón y Cajal, Raquel Serrano Blanch, Enrique Aranda. (2010) TTD consensus document on the diagnosis and management of hereditary colorectal cancer. Clinical and Translational Oncology 12:5, 356-366
CrossRef40
Winand NM Dinjens, Monique E van Leerdam, Anja Wagner. (2010) On the advent of MSI testing of all colorectal cancers and a substantial part of other Lynch syndrome-related neoplasms. Expert Review of Molecular Diagnostics 10:4, 381-384
CrossRef41
Mary B Daly. (2010) Oophorectomy as a preventative measure for ovarian cancer. Therapy 7:3, 241-247
CrossRef42
Isela Quispe, Judith Balmaña. (2010) Desarrollo y aplicación de modelos predictivos en el síndrome de Lynch. Medicina Clínica 134:9, 412-417
CrossRef43
Allison M. Burton, Susan K. Peterson, Salma K. Marani, Sally W. Vernon, Christopher I. Amos, Marsha L. Frazier, Patrick M. Lynch, Ellen R. Gritz. (2010) Health and lifestyle behaviors among persons at risk of Lynch syndrome. Cancer Causes & Control 21:4, 513-521
CrossRef44
David Cunningham, Wendy Atkin, Heinz-Josef Lenz, Henry T Lynch, Bruce Minsky, Bernard Nordlinger, Naureen Starling. (2010) Colorectal cancer. The Lancet 375:9719, 1030-1047
CrossRef45
Kathleen M. Schmeler, Molly S. Daniels, Pamela T. Soliman, Russell R. Broaddus, Michael T. Deavers, Thuy M. Vu, George J. Chang, Karen H. Lu. (2010) Primary Peritoneal Cancer After Bilateral Salpingo-Oophorectomy in Two Patients With Lynch Syndrome. Obstetrics & Gynecology 115:Supplement, 432-434
CrossRef46
Helen Hanson, Shirley Hodgson. (2010) Cancer genetics and reproduction. Best Practice & Research Clinical Obstetrics & Gynaecology 24:1, 3-18
CrossRef47
Ying Zhang, Jian Wang. (2010) Controversies in the Management of Endometrial Carcinoma. Obstetrics and Gynecology International 2010, 1-16
CrossRef48
K. Schulmann, W. Schmiegel. (2010) Hereditäres nichtpolypöses kolorektales Karzinom. Der Gastroenterologe 5:1, 16-22
CrossRef49
James Church. (2010) Prevention of Metachronous Colorectal Cancer in Patients With Lynch Syndrome. Diseases of the Colon & Rectum 53:1, 3-4
CrossRef50
Margot G.F. Van Lier, Anja Wagner, Monique E. Van Leerdam, Katharina Biermann, Ernst J. Kuipers, Ewout W. Steyerberg, Hendrikus Jan Dubbink, Winand N.M. Dinjens. (2010) A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. Journal of Cellular and Molecular Medicine 14:1-2, 181-197
CrossRef51
Nagendra Natarajan, Patrice Watson, Edibaldo Silva-Lopez, Henry T. Lynch. (2010) Comparison of Extended Colectomy and Limited Resection in Patients With Lynch Syndrome. Diseases of the Colon & Rectum 53:1, 77-82
CrossRef52
Lotte H. M. Gerritzen, Nicoline Hoogerbrugge, Angèle L. M. Oei, Fokko M. Nagengast, Maaike A. P. C. Ham, Leon F. A. G. Massuger, Joanne A. Hullu. (2009) Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Familial Cancer 8:4, 391-397
CrossRef53
Analisa DiFeo, Goutham Narla, John A. Martignetti. (2009) Emerging Roles of Kruppel-Like Factor 6 and Kruppel-Like Factor 6 Splice Variant 1 in Ovarian Cancer Progression and Treatment. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:6, 557-566
CrossRef54
Patricia A. Ganz. (2009) Survivorship: Adult Cancer Survivors. Primary Care: Clinics in Office Practice 36:4, 721-741
CrossRef55
Floor J. Backes, Heather Hampel, Katherine A. Backes, Luis Vaccarello, George Lewandowski, Jeffrey A. Bell, Gary C. Reid, Larry J. Copeland, Jeffrey M. Fowler, David E. Cohn. (2009) Are prediction models for Lynch syndrome valid for probands with endometrial cancer?. Familial Cancer 8:4, 483-487
CrossRef56
C. Pox, S. Schmiegel, K. Schulmann, S. Stemmler, H. Schrader, I.A. Adamietz. (2009) Prävention und Diagnose kolorektaler Karzinome. Der Onkologe 15:10, 1033-1048
CrossRef57
Kerrington D. Smith, Miguel A. Rodriguez-Bigas. (2009) Role of Surgery in Familial Adenomatous Polyposis and Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome). Surgical Oncology Clinics of North America 18:4, 705-715
CrossRef58
Daniel B. Eisen, Daniel J. Michael. (2009) Sebaceous lesions and their associated syndromes: Part II. Journal of the American Academy of Dermatology 61:4, 563-578
CrossRef59
Albert de la Chapelle, Glenn Palomaki, Heather Hampel. (2009) Identifying Lynch syndrome. International Journal of Cancer 125:6, 1492-1493
CrossRef60
Floor J. Backes, Marino E. Leon, Iouri Ivanov, Adrian Suarez, Wendy L. Frankel, Heather Hampel, Jeffrey M. Fowler, Larry J. Copeland, David M. O'Malley, David E. Cohn. (2009) Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecologic Oncology 114:3, 486-490
CrossRef61
B.J. Winterhoff, J.N. Bakkum-Gamez, A. Mariani, S.C. Dowdy. (2009) Spezialfälle des Endometriumkarzinoms. Der Onkologe 15:9, 904-911
CrossRef62
B.J. Winterhoff, J.N. Bakkum-Gamez, A. Mariani, S.C. Dowdy. (2009) Special cases in endometrial cancer. Der Onkologe
CrossRef63
Michael Montejo, Theresa L. Werner, David Gaffney. (2009) Current challenges in clinical management of endometrial cancer. Advanced Drug Delivery Reviews 61:10, 883-889
CrossRef64
HT Lynch, PM Lynch, SJ Lanspa, CL Snyder, JF Lynch, CR Boland. (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clinical Genetics 76:1, 1-18
CrossRef65
Ritu Salani, Floor J Backes, Larry J Copeland. (2009) Overview of epithelial ovarian cancer and updates in management strategies. Expert Review of Obstetrics & Gynecology 4:4, 383-399
CrossRef66
Henry T. Lynch, Murray Joseph Casey, Carrie L. Snyder, Chhanda Bewtra, Jane F. Lynch, Matthew Butts, Andrew K. Godwin. (2009) Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Molecular Oncology 3:2, 97-137
CrossRef67
Shilpa Grover, Sapna Syngal. (2009) Genetic testing in gastroenterology: Lynch syndrome. Best Practice & Research Clinical Gastroenterology 23:2, 185-196
CrossRef68
Jan J Koornstra, Marian JE Mourits, Rolf H Sijmons, Annemarie M Leliveld, Harry Hollema, Jan H Kleibeuker. (2009) Management of extracolonic tumours in patients with Lynch syndrome. The Lancet Oncology 10:4, 400-408
CrossRef69
E Barrow, L Robinson, W Alduaij, A Shenton, T Clancy, F Lalloo, J Hill, DG Evans. (2009) Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics 75:2, 141-149
CrossRef70
Ranjit Manchanda, Usha Menon, Rachel Michaelson-Cohen, Uziel Beller, Ian Jacobs. (2009) Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. Current Opinion in Obstetrics and Gynecology 21:1, 31-38
CrossRef71
C. J. Pouchet, N. Wong, G. Chong, M. J. Sheehan, G. Schneider, B. Rosen-Sheidley, W. Foulkes, M. Tischkowitz. (2009) A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. Annals of Oncology 20:4, 681-688
CrossRef72
(2009) Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine 11:1, 35-41
CrossRef73
Glenn E. Palomaki, Monica R. McClain, Stephanie Melillo, Heather L. Hampel, Stephen N. Thibodeau. (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine 11:1, 42-65
CrossRef74
L PALMA, V MARCUS, L GILBERT, G CHONG, W FOULKES. (2008) Synchronous occult cancers of the endometrium and fallopian tube in an MSH2 mutation carrier at time of prophylactic surgery. Gynecologic Oncology 111:3, 575-578
CrossRef75
F LÉCURU, M.A LE FRÈRE BELDA, A.S BATS, L TULPIN, U METZGER, S OLSCHWANG, P LAURENT-PUIG. (2008) Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. International Journal of Gynecological Cancer 18:6, 1326-1331
CrossRef76
F. Lécuru, Y. Ansquer, A.-S. Bats, S. Olschwang, P. Laurent-Puig, F. Eisinger. (2008) Cancer de l’endomètre du syndrome HNPCC. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 37:6, 547-553
CrossRef77
Wendy S Rubinstein, Scott M Weissman. (2008) Managing hereditary gastrointestinal cancer syndromes: the partnership between genetic counselors and gastroenterologists. Nature Clinical Practice Gastroenterology & Hepatology 5:10, 569-582
CrossRef78
Claire E. Wakefield, Bettina Meiser, Judi Homewood, Robyn Ward, Sheridan O'Donnell, Judy Kirk, . (2008) Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk. Cancer 113:5, 956-965
CrossRef79
Maria M. Blokhuis, Paul A. Goldberg, G. Elize Pietersen, Ursula Algar, A. Alvera Vorster, Dhiren Govender, Raj S. Ramesar. (2008) The extracolonic cancer spectrum in females with the common ‘South African’ hMLH1 c.C1528T mutation. Familial Cancer 7:3, 191-198
CrossRef80
Wigdan Al-Sukhni, Melyssa Aronson, Steven Gallinger. (2008) Hereditary Colorectal Cancer Syndromes: Familial Adenomatous Polyposis and Lynch Syndrome. Surgical Clinics of North America 88:4, 819-844
CrossRef81
Henry T. Lynch, Edibaldo Silva, Debrah Wirtzfeld, Pamela Hebbard, Jane Lynch, David G. Huntsman. (2008) Hereditary Diffuse Gastric Cancer: Prophylactic Surgical Oncology Implications. Surgical Clinics of North America 88:4, 759-778
CrossRef82
Janice S. Kwon, Charlotte C. Sun, Susan K. Peterson, Kristin G. White, Molly S. Daniels, Stephanie G. Boyd‐Rogers, Karen H. Lu. (2008) Cost‐effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 113:2, 326-335
CrossRef83
Marion Harris, . (2008) WHY ALL YOUNG BOWEL CANCER PATIENTS SHOULD BE SCREENED FOR LYNCH SYNDROME. ANZ Journal of Surgery 78:7, 531-532
CrossRef84
Larissa A Meyer, Shannon N Westin, Karen H Lu, Michael R Milam. (2008) Genetic polymorphisms and endometrial cancer risk. Expert Review of Anticancer Therapy 8:7, 1159-1167
CrossRef85
Liying Zhang. (2008) Immunohistochemistry versus Microsatellite Instability Testing for Screening Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. The Journal of Molecular Diagnostics 10:4, 301-307
CrossRef86
Mauro Signorelli, Robert Fruscio, Andrea Alberto Lissoni, Cecilia Pirovano, Patrizia Perego, Costantino Mangioni. (2008) Synchronous early-stage endometrial and ovarian cancer. International Journal of Gynecology & Obstetrics 102:1, 34-38
CrossRef87
Kristin C. Jensen, M. Rajan Mariappan, Girish V. Putcha, Amreen Husain, Nicki Chun, James M. Ford, Iris Schrijver, Teri A. Longacre. (2008) Microsatellite Instability and Mismatch Repair Protein Defects in Ovarian Epithelial Neoplasms in Patients 50 Years of Age and Younger. The American Journal of Surgical Pathology 32:7, 1029-1037
CrossRef88
Kathleen M. Schmeler, Karen H. Lu. (2008) Gynecologic cancers associated with Lynch syndrome/HNPCC. Clinical and Translational Oncology 10:6, 313-317
CrossRef89
Kellie S. Matthews, Jacob M. Estes, Michael G. Conner, Upender Manne, Jenny M. Whitworth, Warner K. Huh, Ronald D. Alvarez, J Michael Straughn, Mack N. Barnes, Rodney P. Rocconi. (2008) Lynch Syndrome in Women Less Than 50 Years of Age With Endometrial Cancer. Obstetrics & Gynecology 111:5, 1161-1166
CrossRef90
Mark E Sherman, James V Lacey Jr. 2008. Models of endometrial carcinogenesis. , 813-831.
CrossRef91
I Chirivella, S Rosello, A Insa. 2008. Heriditary cancer syndromes: role ofprevention and screening. , 153-162.
CrossRef92
Henry T. Lynch, Jane F. Lynch, Patrick M. Lynch, Thomas Attard. (2008) Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Familial Cancer 7:1, 27-39
CrossRef93
Kathleen Y Yang, Lee-may Chen. (2008) Gynecologic decisions for women at risk for Lynch syndrome. Expert Review of Obstetrics & Gynecology 3:2, 231-237
CrossRef94
Karen H. Lu. (2008) Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Familial Cancer 7:1, 53-58
CrossRef95
K. Schulmann, S. Stemmler. (2008) Hereditäres Kolonkarzinom. Der Gastroenterologe 3:2, 112-118
CrossRef96
Tusar K. Desai, Donald Barkel. (2008) Syndromic Colon Cancer: Lynch Syndrome and Familial Adenomatous Polyposis. Gastroenterology Clinics of North America 37:1, 47-72
CrossRef97
Joel I. Sorosky. (2008) Endometrial Cancer. Obstetrics & Gynecology 111:2, Part 1, 436-447
CrossRef98
Teresa Ramón, Cajal Asensio. (2008) Cáncer de colon hereditario. Cirugía Española 83:2, 51-52
CrossRef99
Ashley S. Case, Israel Zighelboim, David G. Mutch, Sheri A. Babb, Amy P. Schmidt, Alison J. Whelan, Stephen N. Thibodeau, Paul J. Goodfellow. (2008) Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair. Gynecologic Oncology 108:2, 438-444
CrossRef100
J. N. Bakkum-Gamez, J. Gonzalez-Bosquet, N. N. Laack, A. Mariani, S. C. Dowdy. (2008) Current Issues in the Management of Endometrial Cancer. Mayo Clinic Proceedings 83:1, 97-112
CrossRef101
D. RAMSOEKH, M. E. VAN LEERDAM, A. WAGNER, E. J. KUIPERS. (2007) Review article: detection and management of hereditary non-polyposis colorectal cancer (Lynch syndrome). Alimentary Pharmacology & Therapeutics 26, 101-111
CrossRef102
Henry T Lynch, Murray Joseph Casey. (2007) Prophylactic surgery prevents endometrial and ovarian cancer in Lynch syndrome. Nature Clinical Practice Oncology 4:12, 672-673
CrossRef103
James C. Pavelka, Andrew J. Li, Beth Y. Karlan. (2007) Hereditary Ovarian Cancer—Assessing Risk and Prevention Strategies. Obstetrics and Gynecology Clinics of North America 34:4, 651-665
CrossRef104
Rebecca Byler Dann, Joseph L. Kelley, Kristin K. Zorn. (2007) Strategies for Ovarian Cancer Prevention. Obstetrics and Gynecology Clinics of North America 34:4, 667-686
CrossRef105
Pamela T. Soliman, Karen Lu. (2007) Endometrial Cancer Associated with Defective DNA Mismatch Repair. Obstetrics and Gynecology Clinics of North America 34:4, 701-715
CrossRef106
Fay Kastrinos, Sapna Syngal. (2007) Recently Identified Colon Cancer Predispositions: MYH and MSH6 Mutations. Seminars in Oncology 34:5, 418-424
CrossRef107
Siobhan M. Kehoe, Noah D. Kauff. (2007) Screening and Prevention of Hereditary Gynecologic Cancers. Seminars in Oncology 34:5, 406-410
CrossRef108
Stacey A. South, Mollie Hutton, Carolyn Farrell, Paulette Mhawech-Fauceglia, Kerry J. Rodabaugh. (2007) Uterine Carcinosarcoma Associated With Hereditary Nonpolyposis Colorectal Cancer. Obstetrics & Gynecology 110:Supplement, 543-545
CrossRef109
Lars-Christian Horn, Alexandra Meinel, Romy Handzel, Jens Einenkel. (2007) Histopathology of endometrial hyperplasia and endometrial carcinoma. Annals of Diagnostic Pathology 11:4, 297-311
CrossRef110
Fabrice Lécuru, Ulrike Metzger, Catherine Scarabin, Marie Aude Le Frère Belda, Sylviane Olschwang, Pierre Laurent Puig. (2007) Hysteroscopic findings in women at risk of HNPCC. Results of a prospective observational study. Familial Cancer 6:3, 295-299
CrossRef111
K. DOMANSKA, S. MALANDER, A. MÅSBÄCK, M. NILBERT. (2007) Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. International Journal of Gynecological Cancer 17:4, 789-793
CrossRef112
Beth Y. Karlan, Andrew Berchuck, David Mutch. (2007) The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice. Obstetrics & Gynecology 110:1, 155-167
CrossRef113
Lee-may Chen, Kathleen Y. Yang, Sarah E. Little, Michael K. Cheung, Aaron B. Caughey. (2007) Gynecologic Cancer Prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer Families. Obstetrics & Gynecology 110:1, 18-25
CrossRef114
M.J. Duffy, A. van Dalen, C. Haglund, L. Hansson, E. Holinski-Feder, R. Klapdor, R. Lamerz, P. Peltomaki, C. Sturgeon, O. Topolcan. (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. European Journal of Cancer 43:9, 1348-1360
CrossRef115
Katarina Domanska, Mef Nilbert, Maria Soller, Barbro Silfverberg, Christina Carlsson. (2007) Discrepancies Between Estimated and Perceived Risk of Cancer among Individuals with Hereditary Nonpolyposis Colorectal Cancer. Genetic Testing 11:2, 183-186
CrossRef116
Veronica R. Collins, Bettina Meiser, Obioha C. Ukoumunne, Clara Gaff, D James St. John, Jane L. Halliday. (2007) The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing. Genetics in Medicine 9:5, 290-297
CrossRef117
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Seiden, Michael V., Patel, Devanshi, O'Neill, Mary Jane, Oliva, Esther, . (2007) Case 13-2007. New England Journal of Medicine 356:17, 1760-1769
Full Text118
Kenneth D. McMilin, Susmita Dasgupta. (2007) Allogeneic Transplantation and the Risk for Transmission of Genetic Disease: The Heritable Cancer Disorders. Stem Cells and Development 16:2, 191-212
CrossRef119
Jose G. Guillem, Emily Glogowski, Harvey G. Moore, Khedoudja Nafa, Arnold J. Markowitz, Jinru Shia, Kenneth Offit, Nathan A. Ellis. (2007) Single-amplicon MSH2 A636P Mutation Testing in Ashkenazi Jewish Patients With Colorectal Cancer. Annals of Surgery 245:4, 560-565
CrossRef120
Y. Nancy You, Vipul T. Lakhani, Samuel A. Wells. (2007) The Role of Prophylactic Surgery in Cancer Prevention. World Journal of Surgery 31:3, 450-464
CrossRef121
Stacy B Menees, Dee E Fenner. (2007) Colon cancer screening in women. Women's Health 3:2, 163-172
CrossRef122
Laura Renkonen-Sinisalo, Ralf Bützow, Arto Leminen, Pentti Lehtovirta, Jukka-Pekka Mecklin, Heikki J. Järvinen. (2007) Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. International Journal of Cancer 120:4, 821-824
CrossRef123
Susan M Domchek, Timothy R Rebbeck. (2007) Prophylactic oophorectomy in women at increased cancer risk. Current Opinion in Obstetrics and Gynecology 19:1, 27-30
CrossRef124
Svetlana Mironov, Oguz Akin, Neeta Pandit-Taskar, Lucy E. Hann. (2007) Ovarian Cancer. Radiologic Clinics of North America 45:1, 149-166
CrossRef125
R.L. Coleman. (2007) Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome. Yearbook of Obstetrics, Gynecology and Women's Health 2007, 352-353
CrossRef126
C. Kurzeder, G. Sauer, R. Kreienberg. (2007) Epidemiologie des Endometriumkarzinoms. Der Gynäkologe 40:1, 10-13
CrossRef127
José G. Guillem, William C. Wood, Jeffrey F. Moley, Andrew Berchuck, Beth Y. Karlan, David G. Mutch, Robert F. Gagel, Jeffrey Weitzel, Monica Morrow, Barbara L. Weber, Francis Giardiello, Miguel A. Rodriguez-Bigas, James Church, Stephen Gruber, Kenneth Offit. (2006) ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. Annals of Surgical Oncology 13:10, 1296-1321
CrossRef128
Nicole Urban, Charles Drescher. (2006) Current and future developments in screening for ovarian cancer. Women's Health 2:5, 733-742
CrossRef129
Robert Gryfe. (2006) Clinical Implications of Our Advancing Knowledge of Colorectal Cancer Genetics: Inherited Syndromes, Prognosis, Prevention, Screening and Therapeutics. Surgical Clinics of North America 86:4, 787-817
CrossRef130
Deepa S Subramaniam, Claudine Isaacs. (2006) Does prophylactic surgery reduce the risk of gynecologic cancers arising from the Lynch syndrome?. Nature Clinical Practice Oncology 3:8, 426-427
CrossRef131
Alexandra King. (2006) Prophylactic surgery reduces risk of gynecologic cancers in women with Lynch syndrome. Nature Clinical Practice Oncology 3:4, 175-175
CrossRef132
Offit, Kenneth, Kauff, Noah D., . (2006) Reducing the Risk of Gynecologic Cancer in the Lynch Syndrome. New England Journal of Medicine 354:3, 293-295
Full Text133
Steffen Pistorius. (2006) Resektionsausmaß und Therapiekonzept bei hereditärem, nicht Polyposis-assoziiertem kolorektalem Karzinom (HNPCC) – Indexpatient: chirurgische Strategie. Chirurgische Gastroenterologie 22:1, 1-5
CrossRef
